The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Open accessAbstract
Purpose: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. Methods: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data. Results: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur. Prostate cancers progressing despite castrate levels of testosterone are considered castration resistant and not hormone refractory. Eligibility is defined using standard disease assessments to authenticate disease progression, prior treatment, distinct clinical subtypes, and predictive models. Outcomes are reported independently for prostate-specific antigen (PSA), imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response. In most trials, early changes in PSA and/or pain are not acted on without other evidence of disease progression, and treatment should be continued for at least 12 weeks to ensure adequate drug exposure. Bone scans are reported as “new lesions” or “no new lesions,” changes in soft-tissue disease assessed by RECIST, and pain using validated scales. Defining eligibility for prevent/delay end points requires attention to estimated event frequency and/or random assignment to a control group. Conclusion: PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationU.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationBubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationBilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Self-citationThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Self-citationHolzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Self-citationMostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., Wynne, C., Murray, R., Zinner, N. R., Schulman, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.529 · Cited by 496
Self-citationTestosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Smaletz, O., Scher, H. I., Small, E. J., Verbel, D. A., McMillan, A., Regan, K., Kelly, W. K., & Kattan, M. W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.021 · Cited by 386
Self-citationCarducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D. D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.176 · Cited by 371
Self-citationArmstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1036 · Cited by 359
Self-citationDeveloping patient-reported outcome measures for pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Burke, L. B., Gershon, R., Rothman, M., Scott, J., Allen, R. R., Atkinson, H. J., Chandler, J., Cleeland, C., et al. (2006) · Pain · doi:10.1016/j.pain.2006.09.028 · Cited by 301
Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., & Eisenberger, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4769 · Cited by 275
Self-citationTargeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., & Tilley, W. D. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00525 · Cited by 240
Self-citationClinical states in prostate cancer: toward a dynamic model of disease progression
Scher, H. I., & Heller, G. (2000) · Urology · doi:10.1016/s0090-4295(99)00471-9 · Cited by 232
Self-citationSeidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., & Curley, T. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37426-8 · Cited by 200
Self-citationMaximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853
Denis, L. J., Keuppens, F., Smith, P. H., Whelan, P., Carneiro de Moura, J. L., Newling, D., Bono, A., Sylvester, R., & EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center, F. T. (1998) · European Urology · doi:10.1159/000019546 · Cited by 167
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
Scher, H. I., Morris, M. J., Kelly, W. K., Schwartz, L. H., & Heller, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0109 · Cited by 130
Self-citationKawakami, J., Cowan, J. E., Elkin, E. P., Latini, D. M., DuChane, J., & Carroll, P. R. (2006) · Cancer · doi:10.1002/cncr.21799 · Cited by 107
Is the Randomized Clinical Trial the Gold Standard of Research?
Simon, S. D. (2001) · Journal of Andrology · doi:10.1002/j.1939-4640.2001.tb03433.x · Cited by 73
Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer
Smith, P. H., Bono, A. V., da Silva, F. C., et al. (1990) · Cancer · doi:10.1002/cncr.1990.66.s5.1009 · Cited by 72
Vickers, A. J., Ballen, V., & Scher, H. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0909 · Cited by 69
Self-citationThe Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents
Dixon, S. C., Knopf, K., & Figg, W. D. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01480-7 · Cited by 62
Self-citationPost-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
Fleming, M. T., Morris, M. J., Heller, G., & Scher, H. I. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0664 · Cited by 61
Self-citationThe Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
Yossepowitch, O., Bianco, F. J., Eggener, S. E., Eastham, J. A., Scher, H. I., & Scardino, P. T. (2006) · European Urology · doi:10.1016/j.eururo.2006.10.045 · Cited by 58
Self-citationScher, H. I., Zhang, Z., Nanus, D. M., & Kelly, W. K. (1996) · Urology · doi:10.1016/s0090-4295(96)80011-2 · Cited by 47
Self-citationImpact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy
Nelius, T., Klatte, T., de Riese, W. T. W., & Filleur, S. (2007) · International Urology and Nephrology · doi:10.1007/s11255-007-9221-y · Cited by 38
Second-Line Chemotherapy for Prostate Cancer: Patient Characteristics and Survival
Beekman, K. W., Fleming, M. T., Scher, H. I., Slovin, S. F., Ishill, N. M., Heller, G., & Kelly, W. K. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.015 · Cited by 33
Self-citation
Cited by
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citation
Metadata
- Authors
- Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., Petrylak, D., Kantoff, P., Basch, E., Kelly, W. K., Figg, W. D., Small, E. J., Beer, T. M., Wilding, G., Martin, A., & Hussain, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-01
- Volume
- 26
- Issue
- 7
- Pages
- 1148-1159
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167331614
- Cited by
- 2,241
- References
- 33
- FWCI
- 69.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.